home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Understanding the Statistical Thinking in Clinical Research for Drug Development: Control Overall False Positive Rate in Clinical Trials to Ensure the Validity of Trial Results

 
  July 23, 2011  
     
 
Shanghai Everbright Convention & Exhibition Center Internati , Shanghai China
Oct 23 2011 8:00AM - Oct 24 2011 5:00PM


Learn Statistical Methodologies for Better Design and Control of Clinical Trials
This two-day workshop will provide in-depth, practical, and basic-to-intermediate level tutorial in the design and statistical methodologies in clinical trials. The workshop features opportunities for statistical learning and increasing your clinical trial success.
FEATURED TOPICS
• Multiple comparisons and endpoints
• Interim analysis
• Sample size re-estimation
Why are they so common in clinical trials, what do they refer to, how to handle these issues, and what is their relationship to the issue of false positive finding of clinical trials outcomes, which is one of the regulatory focuses in the clinical evaluation of new drug application? This course will focus on these concepts and issues. Real life clinical trial examples will be used to illustrate these concepts and underlying statistical methodologies.
 
Event Code:
11977

 
 
 
Organized by: DIA China
Invited Speakers: See website for speaker information
 
Deadline for Abstracts: Call contact
 
Registration:

https://kellen-china.ungerboeck.com/reg/reg_p1_form.aspx?oc=30&ct=DIAMEETING&eventid=5014

Tel: +86-10-59231109 Fax: +86-10-59231090, www.diahome.org, dia@diachina.org 

E-mail: dia@diachina.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.